%20(1).svg)
Erica Schlesinger is Serán’s Vice President of Technical Development. She leads a team that applies scientific rationale and engineering design to problem-solving and pharmaceutical product development. Her research interests include spray-dried biologics (mAb, Phage, Virus, Whole Cells) and controlled-release technologies for long-acting therapeutics.
Erica has over 15 years of experience in pharmaceutical formulation development, process chemistry, and the early-stage development of novel drug delivery systems, and prior to joining Serán, she worked at Genentech, Seattle Genetics, and Regeneron.
Erica holds an undergraduate degree in Chemical Engineering from Cornell University and a Ph.D. in Bioengineering from the Joint Graduate Group in Bioengineering at the University of California San Francisco and UC Berkeley.
Erica Schlesinger, Ph.D.
VP of Technical Development
Dan Smithey, Ph.D.
President & CEO of Serán
View Bio
Dan Smithey, Ph.D.
President & CEO of Serán
45+ Years Drug Dev
Dr. Smithey is the President, CEO, and Co-founder of Serán BioScience with over 30 years of experience in pharmaceutical R&D. He led the development of several breakthrough therapies, including Tukysa® for metastatic breast cancer. A recognized innovator, he has founded multiple biotech ventures and holds over 50 patents.
Kevin Nepveux
Pfizer Global Commercial Manufacturing
View Bio
Kevin Nepveux
Pfizer Global Commercial Manufacturing
Years at Pfizer, other companies
Kevin is a chemical engineer with over 40 years at Pfizer, where he played key roles in both R&D and manufacturing. He contributed to the development and production of several major therapies and led global initiatives in tech transfer, scale-up, and new technology. A career highlight was his leadership in Pfizer’s COVID-19 vaccine manufacturing effort.
Will Cozean
Managing Director Bain: Capital Life Sciences
View Bio
Will Cozean
Managing Director Bain: Capital Life Sciences
Experience with life science industry
Mr. Cozean is a Managing Director at Bain Capital Life Sciences and serves on the board of Serán BioScience. He brings deep experience in healthcare investing, with prior roles at Bain Capital Private Equity and McKinsey & Co. He holds an MBA from Harvard Business School, where he was a Baker Scholar, and a BS in Commerce from the University of Virginia.
Gaurav Aggarwal
Managing Director: Vivo Capital
View Bio
Gaurav Aggarwal
Managing Director: Vivo Capital
Experience with life science industry
Dr. Aggarwal is a Managing Partner at Vivo Capital with over two decades of experience investing in the life sciences sector. He has held leadership roles across venture capital, public market investing, and biopharma operations, including as Chief Business Officer at Ocera Therapeutics. Dr. Aggarwal holds an M.D. from Columbia University and a B.S. from Cornell University.
Mike Preigh
1490 Pharma LLC
View Bio
Mike Preigh
1490 Pharma LLC
Experience with life science indusry
Dr. Mike Preigh brings over 30 years of experience in pharmaceutical development and manufacturing. He most recently served as CTO at Day One Biopharmaceuticals, where he led the CMC efforts for the approval and launch of Ojemda (tovorafenib). His career includes leadership roles at Array BioPharma and Pfizer, with a track record of advancing numerous therapies from IND through commercialization.
Aslam Malik
SK Pharmteco: Ampac
View Bio
Aslam Malik
SK Pharmteco: Ampac
Experience with life science indusry
Dr. Aslam Malik is an accomplished leader with over 35 years in the pharmaceutical and chemical industry. He was most recently CEO of SK pharmteco and previously led AMPAC Fine Chemicals. A recognized innovator with over 50 patents, Dr. Malik holds a Ph.D. in Organic Chemistry and has served on numerous industry and non-profit boards.
.svg)